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http://dx.doiabstractBACKGROUND:We assessed the clinical utility of routine electroencephalography (EEG) in the prediction of epilepsy
onset in asymptomatic infants with tuberous sclerosis complex. METHODS: This multicenter prospective observa-
tional study recruited infants younger than 7 months, seizure-free and on no antiepileptic drugs at enrollment,
who all underwent serial physical examinations and video EEGs throughout the study. Parental education on
seizure recognition was completed at the time of initial enrollment. Once seizure onset occurred, standard of care
was applied, and subjects were followed up until 24 months. RESULTS: Forty patients were enrolled, 28 older than
12 months with completed EEG evaluation at the time of this interim analysis. Of those, 19 (67.8%) developed
seizures. Epileptic spasms occurred in 10 (52.6%), focal seizures in ﬁve (26.3%), generalized tonic-clonic seizure in
one (5.3%), and a combination of epileptic spasms and focal seizures in three (15.7%). Fourteen infants (73.6%) had
the ﬁrst emergence of epileptiform abnormalities on EEG at an average age 4.2 months, preceding seizure onset by
a median of 1.9 months. Hypsarrhythmia or modiﬁed hypsarrhythmia was not found in any infant before onset of
epileptic spasms. All children with epileptiform discharges subsequently developed epilepsy (100% positive
predictive value), and the negative predictive value for not developing epilepsy after a normal EEG was 64%.
CONCLUSIONS: Serial routine EEGs in infants with tuberous sclerosis complex is a feasible strategy to identify in-
dividuals at high risk for epilepsy. The most frequent clinical presentation was epileptic spasms followed by focal
seizures, and then a combination of both seizure types.
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Tuberous sclerosis complex (TSC) is an autosomal
dominant disease that affects approximately one in 6000
people, represents one of the most common genetic causesry:
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org/10.1016/j.pediatrneurol.2015.09.013of epilepsy,1-3 and is caused by TSC1 or TSC2 mutation. The
neurological manifestations in TSC are common and in
children represent the most disabling problems of the dis-
ease, including epilepsy, intellectual disabilities, psychiatric
problems, and autism. Epilepsy is particularly prevalent,
affecting about 80% of individuals with TSC4-6 with over 60%
having seizures that are severe and refractory.4,7,8 Almost
half of infants with TSC develop epileptic spasms, which is
associated with poor neurological prognosis.4
Increasingly TSC is diagnosed at a young age before the
onset of epilepsy from non-neurological ﬁndings, such asnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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a unique opportunity to identify and validate a biomarker for
epilepsy. A predictive biomarker would allow earlier inter-
vention that may alter or curtail epileptogenesis and its
adverse effects. A recent open-label study suggests that
treating patients with TSC with an abnormal electroenceph-
alography (EEG) before onset of epileptic spasms with
vigabatrin may improve neurological outcome.10 An earlier
retrospective study reported similar beneﬁt with early treat-
ment.11 Nonetheless, the use of clinical EEG as a reliable
biomarker of epilepsy has not been rigorously validated and
has been limited to retrospective analyses subject to referral,
recording, and recall biases.4,12 Our prospective study pro-
vides a unique opportunity to document the evolution of
epileptogenesis, development of clinical seizures, and the
utility of EEG as an early biomarker for epilepsy in TSC.Methods
Subject recruitment
Infants with TSC in this multicenter prospective observation study
were enrolled from the neonatal nursery, pediatric cardiology, general
pediatrics, genetics, pediatric neurology, and obstetrics/perinatology/
maternalefetal medicine clinics. TSC diagnosis was based on clinical
features (i.e., cardiac rhabdomyomas, intracranial tubers or subependymal
nodules or giant cell astrocytomas, characteristic skin ﬁndings, and/or
other evidence on prenatal or perinatal cardiac echocardiography,
neuroimaging, and skin examinations) or genetic diagnosis.13
Each infant with TSC enrolled met all the following inclusion criteria:
(1) age <7 months, (2) seizure-free at enrollment, and (3) the genetic or
clinical diagnosis for TSC.13 Infants were excluded if any one of the
following criteria was present: (1) age 7 months, (2) history of seizures
of any type, or (3) current or past treatment with vigabatrin or inhibitors
of the mammalian target of rapamycin, before study enrollment. Pre-
maturely born infants with TSC as young as 32 weeks’ gestation could
participate only if there were no medical complications from prematu-
rity, involving the brain or other major organs, such as hypoxic-ischemic
encephalopathy, any intracranial hemorrhage, necrotizing enterocolitis,
any respiratory diagnoses requiring ventilator support, or cardiovascular
compromise. The earliest time of enrollment for these premature infants
was when they reached term (37 weeks’ gestation).
Infants with TSC were recruited from the TSC centers at each of the
ﬁve sites (University of Alabama at Birmingham, University of California
at Los Angeles, Boston Children’s Hospital, Cincinnati Children’s Hospital
Medical Center, and University of Texas Medical School at Houston).Study design
This study was approved by the institutional review boards of all ﬁve
institutions. Parental consent was obtained for all subjects. At designated
time points following enrollment (1.5, 3, 4.5, 6, 9, 12, 18, and 24 months
chronological age), physical and neurological examination and a 1-hour
research video EEG (to include both sleep and wakefulness) were
performed. The 1 hour duration of the video EEG was chosen to maxi-
mize capturing both wakefulness and sleep during the same study, yet
sufﬁciently brief to use in and extend to the clinical setting, as well as
taking into consideration families’ time commitment and staying within
funding constraints.
Subjects referred for initial screening and enrollment were seen
within 2 weeks. Initial evaluation included physical and neurological
examination and baseline video EEG (1 hour wakefulness and sleep). As
part of our research protocol, a seizure recognition educational video
was shown to the parents or caregivers at the time of enrollment.
Enrolled subjects were followed up until age 2 years.
If the infant or child at any point in the study developed seizures,
history and additional clinical video EEG(s) of varying duration werecompleted to conﬁrm epilepsy onset, and antiepileptic drug (AED)
treatment was initiated at the managing neurologist’s discretion as
dictated by individual clinical scenarios, but this clinical informationwas
recorded, as were all medical therapies throughout the duration of the
study. The research video EEGs continued at the designated time points
stated above, even after clinical seizure onset.
In addition to the scheduled serial research 1-hour video-EEG studies
to monitor for the development and evolution of EEG abnormalities, the
parent or caregiver maintained a seizure log throughout the study. Once
a diagnosis of seizures was made, the subject continued in the study to
monitor developmental progress, seizure control, and response to AEDs.
Video-EEG acquisition and interpretation
Video EEGs were uniformly acquired across all ﬁve TSC centers, with
standard 23 electrodes placed according to the 10-20 international place-
ment system. All video-EEG studies were recorded for 1 hour, incorpo-
rating both sleep andwakefulness, at a high sampling rate of 2000Hz,with
a high-frequency and low-pass ﬁlter of 500 Hz. All video EEGs from all ﬁve
sites were anonymized, then uploaded to a secure central server and
located and maintained at the University of California at Los Angeles. To
view the video EEGs from all ﬁve sites, which collectively used three
different video-EEG vendors, video-EEG analysiswas viewed digitallywith
Persyst software (San Diego, CA), in the standard timescale of 30 mm/sec
and standard ﬁlter settings of 1-Hz low-frequency ﬁlter (high pass) and
70 Hz high frequency (low pass), along with a 60-Hz notched ﬁlter.
To render a more balanced interpretation, each video-EEG study was
reviewed by two independent central EEG reviewers (JMP, MG), who are
both board-certiﬁed pediatric electroencephalographers and blinded to
all clinical information except the age of the subject necessary for the
EEG interpretation. Differences in the EEG interpretation, when present,
were adjudicated by a third, blinded board-certiﬁed pediatric electro-
encephalographer (JYW).
The EEG results were classiﬁed based on age-appropriate norms, as
either normal or abnormal. EEG abnormalities were evaluated in terms
of the presence or absence of background abnormalities, such as
generalized or focal slowing, epileptiform discharges (focal, regional,
bilateral, or generalized spike or spike and wave discharges), (modiﬁed)
hypsarrhythmia, voltage attenuation, as well as clinical and/or electro-
graphic seizures, in accordance with the National Institutes of Neuro-
logical Disorders and Stroke Common Data Element Tools for Epilepsy.
Statistical analysis
The study design made the following assumptions for statistical
sample size. In a population of patients with TSC the study assumed the
incidence of epilepsy to be 85% and that the overall frequency of
epileptiform discharges is 50%. Based on the statistical analysis of the
preliminary data from the University of Alabama Birmingham and the
University of California Los Angeles, enrolling 30 patients results in>80%
power at a nondirectional alpha of 0.05 assuming that the ratio of pa-
tients with normal EEG versus EEG with epileptiform discharges will
vary from 0.2 to 0.5. The association between epileptiform discharges
and epilepsy was analyzed by multiple methods, performed by a stat-
istician at the University of Alabama Birmingham (GC): (1) time-to-event
survival analysis to determine the temporal relationship between
epileptiform discharges and seizure onset, (2) multivariable Cox pro-
portional hazard analysis, to assess the contribution of multiple variables
to development of epilepsy, and (3) logistical regression analysis to
determine the strength of association between epileptiform discharges
and epilepsy at the end of the 24-month follow-up period.
Results
Cohort and clinical characteristics
A total of 40 subjects were prospectively enrolled into
the study (Table 1). At the time of the February 1, 2015 data
cut-off for this interim analysis, 28 infants were older than
TABLE 1.
Summary of Infants With TSC Over Age 12 Months
Subject Race Gender TSC1/TSC2 Age Enrolled
(months)
Age EEG
Abnormal
(months)
EEG Abnormality Age Clinical
Seizure Onset
(months)
Clinical
Seizure
Type(s)
Age at
Data Cut-off
(months)
1 Caucasian Male NMI 5.4 16
2 Caucasian Male Not tested 3.8 15
3 Caucasian Female Not tested 2.1 22
4 Caucasian Female TSC2 1.4 18
5 Caucasian Female TSC1 7.2 20
6 Caucasian Male TSC2 2.1 25
7 Caucasian Male TSC2 1.5 24
8 Caucasian Female TSC1 7 27
9 Caucasian Male TSC1 4.4 26
10 Caucasian Female TSC2 2.3 6 ES 13
11 Caucasian Female TSC1 2.6 5.5 GTC 15
12 Caucasian Female TSC2 1.5 2 Focal 14
13 African American Female TSC2 0.4 11 Focal 14
14 Caucasian Female TSC2 1.6 3.5 ES 20
15 Caucasian Male TSC2 0.7 4.2 Focal spikes 6 Focal þ ES 15
16 Caucasian Female TSC1 3.3 3.4 Regional spikes 4 ES 12
17 Caucasian Female TSC2 6.5 6.5 Regional spikes 8 ES 17
18 Caucasian Male TSC2 6 9 Regional spikes 12.5 ES 16
19 Caucasian Male TSC2 1.1 4 Regional spikes 7 ES 17
20 Caucasian Female TSC2 4 4 Bilateral spikes 5.5 ES 15
21 Caucasian Male TSC2 3.9 4 Regional spikes 5 ES 18
22 Caucasian Male TSC2 1.1 6 Bilateral spikes 6.2 ES 22
23 Asian Male TSC2 1.4 1.5 Focal spikes 3.5 Focal 21
24 Caucasian Female TSC2 2.5 4 Bilateral spikes 6 Focal þ ES 20
25 American Indian Male TSC2 1.5 1.6 Bilateral spikes 3.5 Focal 20
26 Hispanic Female TSC2 6 6 Focal spikes 20 Focal 29
27 Caucasian Male TSC2 4.2 4.2 Bilateral spikes 6 ES 28
28 Caucasian Male TSC2 1.1 1.2 Bilateral spikes 6 ES þ Focal 25
Abbreviations:
EEG ¼ Electroencephalogram
ES ¼ Epileptic spasms
GTC ¼ Generalized tonic clonic seizure
TSC ¼ Tuberous sclerosis complex
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Three additional subjects older than 12 months were
excluded since most recent EEG analysis by the blinded
reviewers was not completed at the time of cut-off. Of the
remaining subjects, three had either electrographic seizures
or epileptiform discharges on EEG and were excluded
because they were treated with AEDs before the onset of
clinical seizures. These subjects could not be included in the
statistical calculation for positive and negative predictive
values because they had received a therapeutic interven-
tion. The remaining six subjects were excluded from this
interim analysis because they were still younger than
12 months and therefore needed longer follow-up time.
Gender was distributed evenly among the 28 infants
included for the interim analysis, and the average age at
time of enrollment was 2.7 2.0 months. Of the 28 subjects
enrolled, 26 underwent TSC genetic testing, 20 (76.9%) had
a pathologic mutation in TSC2. Mutations in TSC1 were
identiﬁed in ﬁve (19.2%). In 1 (3.8%), no mutation in either
TSC1 or TSC2 was found.
In this cohort of 28 infants older than 12months,19 (67.9%)
developed clinical seizures during the observation period.
The average age at time of seizure onsetwas 6.74.1months,
the youngest within age 2.0 months and the oldest at age
20 months. Epileptic spasms were the most common seizure
type and occurred in 10 infants (52.6%). Focal seizuresoccurred either as the sole seizure type (ﬁve subjects, 26.3%)
or with epileptic spasms (three subjects, 15.8%). In contrast,
seizures with generalized onset were rare, with generalized
tonic-clonic seizures occurring only in one (5.3%) subject, and
no other clinical seizure types were reported (Table 2).
Of these EEG interictal and ictal ﬁndings, the presence of
epileptiform discharges preceded the onset of ﬁrst clinical
seizure in 14 of 19 infants (73.7%), which occurred between
ages 1.2 and 9.0 months (Table 2). The interval between the
ﬁrst EEG with epileptiform discharges and the ﬁrst clinical
seizure was an average of 2.8  3.4 months, median of
1.9 months (interquartile range 1.5, 3.0 months). No epilep-
tiformdischargeswere detectedwith anyof the video EEGs in
ﬁve subjects (26.3%) before the onset of clinical seizures.
Seizure type in this latter group included focal seizures,
epileptic spasms, and generalized tonic-clonic seizure (Fig 2).
The remaining nine infants of the cohort of 28 have
remained seizure-free, on no AED, at the time of this
interval analysis, and all nine infants have had normal video
EEGs, without the presence of epileptiform discharges on
any of the video EEGs (Table 3).
The positive predictive value (PPV), or how often the
presence of a biomarker can correctly predict the disease in
a population, can be determined from the ratio of true
positives (those subjects with both abnormal EEG and
subsequent seizures) to the sum of true positives and false
TABLE 2.
Clinical Seizure Semiology and EEG Characteristics
Seizure characteristics in 19 subjects who have had a clinical
seizure since enrollment, by group:
Seizure Type Epileptiform
Discharges
(n ¼ 14)
Normal EEG
(n ¼ 5)
Focal seizures 3 2
Epileptic spasms 8 2
Focal seizures þ epileptic spasms 3 0
Generalized seizures 0 1
EEG characteristics in 19 subjects who have had a clinical seizure
since enrollment:
Fourteen of 19 (73.6%) had epileptiform activity detected on EEG
before the onset of clinical seizures
Average
(months)
Median
(months)
Age at time of ﬁrst epileptiform
discharges
4.2 (S.D. ¼ 2.1) 4.0
Age at time of ﬁrst clinical seizure 6.7 (S.D. ¼ 4.1) 6.0
Time interval between
epileptiform discharges and
seizure
2.8 (S.D. ¼ 3.4) 1.9
Five of 19 (26.3%) had no epileptiform activity detected on EEG
before the onset of clinical seizures
Subject ID Last Normal
EEG (months)
Clinical Seizure
Onset (months)
10 4 6
11 4 5.5
12 1.5 2
13 9 11
14 1.5 3.5
Abbreviation:
EEG ¼ ElectroencephalographyFIGURE 1.
Cohort of study participants with tuberous sclerosis complex. EEG,
electroencephalography.
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seizures). The corresponding PPV (Table 3) for the presence
of epileptiform activity on an EEG preceding the develop-
ment of clinical seizure onset in infants with TSC is then
14/(14 þ 0), or 100% CI (76.8%, 100.0%).
Similarly, the negative predictive value (NPV), or how
often the absence of a biomarker can correctly predict the
nondisease state in a population, is determined from the
ratio of true negatives (subjects with both normal EEG and
no seizures) to the sum of true negatives and false negatives
(subjects with normal EEG but subsequently developing
seizures). The corresponding NPV (Table 3) of the absence
of epileptiform activity on the EEG and no subsequent
epilepsy in infants with TSC is then 9/(9 þ 5), or 64.3% CI
(35.1%, 87.2%).
The other EEG ﬁndings of focal or generalized slowing,
attenuation, hypsarrhythmia or modiﬁed hypsarrhythmia,
and ictal events did not consistently precede the onset of
clinical seizures, and none reached statistical signiﬁcance.Discussion
This prospective multicenter observational study pro-
vides unique insight into the development of epilepsy in
TSC and the clinical utility of serial EEGs in the identiﬁcationof patients at high risk for impending seizure onset. This
preliminary report is driven by compelling strength of
interim analysis and provides early supportive data for risk
stratiﬁcation in planned prospective research on effects of
pre-emptive antiepileptic treatment in TSC.
The risk for epilepsy in TSC has been previously estimated
to be 80%, based on retrospective studies in patients of all
ages, including older children and adults.4,14,15 Determining
prevalence in infants is more difﬁcult as not all the studies
separated their analyses into younger cohorts. Jozwiak et al.14
reported seizures present by age 2 years in 83%, whereas
Chu-Shore et al.4 reported 63% by age 1 year and 82% by age
3 years. Using an observational study design inwhich infants
were enrolled before seizure onset, and followed up pro-
spectively, we calculated in this study the incidence of in-
fants with TSC developing clinical seizures before age 2 years
as 67.8 %. Although our approach overcomes recall and
reporting bias inherent to retrospective studies, the estimate
in this prospective study may yet underestimate the true
incidence, as not all subjects have been observed past age
24 months. Continuing to follow our present cohort pro-
spectively will allow more deﬁnitive calculation of annual
and cumulative incidence of epilepsy for infants with TSC, by
age, throughout infancy and childhood.
Only one prior published study has evaluated EEG ﬁnd-
ings in infants with TSC before the onset of seizures, con-
sisting of ﬁve subjects.16 Patients were enrolled from age
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EEG abnormalities were detected in four subjects between
ages 0.5 and 5.0 months, all of whom (100%) subsequently
developed seizures within 1-8 days of the ﬁrst abnormal
EEG. The remaining subject with a normal EEG never
developed clinical seizures. In this study, we found a similar
high correlation between epileptiform discharges and
subsequent seizures, with the average age when epilepti-
form discharges were ﬁrst detected as 4.2 months. How-
ever, sensitivity was notably lower (73.7%) and with a much
longer time interval between epileptiform discharges and
clinical seizure onset that averaged 2.8 months and median
of 1.9 months. Our study involved multiple centers, a larger
cohort than previous studies, and multiple blinded EEG
readers, adding additional patient diversity, power, and
scientiﬁc rigor to the calculated lower limit of sensitivity. An
unresolved variable that could contribute to the differences
observed is the frequency of surveillance EEGs in theTABLE 3.
Statistical Analysis Summary
Clinical
seizure
No Clinical
Seizure
Epileptiform discharges 14 0
No epileptiform discharges/Normal
electroencephalography
5 9
Sensitivity
(%)
Speciﬁcity
(%)
Positive Predictive
Value (%)
Negative Predictive
Value (%)
73.7 100 100 64asymptomatic cohort. The every 6 weeks EEG at earlier time
points in our study was chosen to balance study sensitivity
with clinical feasibility for participating families. This longer
time interval between scheduled EEGs, especially at later
time points when expanded to 3-6emonth intervals, may
also explain the relatively high false-negative rate observed
(and corresponding calculated NPV) in our study. The
longer interval between scheduled EEGs increases the
likelihood that newly emerging epileptiform abnormalities
before the onset of clinical seizures may have gone unde-
tected in the interim. However, the calculated time between
epileptiform activity and seizures was an average 2.8 months,
median 1.9 months. We suspect that with more frequent
sampling, the interval time, here measured only in monthly
increments, would likely be shorter with the possibility of
showing higher sensitivity and lower NPV. A sizeable win-
dow between epileptiform discharges and clinical seizure
onset is key, as such a window provides a unique and
feasible opportunity to design and implement anti-
epileptogenic treatment strategies that may delay or pre-
vent clinical seizure onset.
In our study infants with TSC are as likely to present with
focal seizures, epileptic spasms, or focal seizures mixed
with epileptic spasms (either concurrently or subsequently
to onset of focal seizures). Furthermore, similar to results of
the Domanska-Pakie1a et al. study,16 classic or modiﬁed
hypsarrhythmia was not found in any infant before the
onset of focal seizures or epileptic spasms. This would
suggest that classic or modiﬁed hypsarrhythmia, reported
to occur in up to 71% of patients with TSC and clinical
epileptic spasms,17 occurs after seizure onset and corre-
sponds to later events in the epileptogenesis process. These
observations on the evolution of epilepsy onset in infants
with TSC have an important impact on clinical manage-
ment, as treatment delay may adversely affect long-term
epilepsy and developmental outcome.11,17 First, parents
and clinicians should know that either focal-onset seizures
or epileptic spasms may be an initial seizure manifestation
in infants with TSC. Second, because hypsarrhythmia may
follow epileptic spasms, clinicians should not wait for
hypsarrhythmia, either in the classic or modiﬁed form, to
appear on EEG before initiating appropriate treatment for
epileptic spasms. Finally, the earliest signs of seizures,
whether focal seizures, epileptic spasms, or a mix thereof,
may be very subtle and could go unrecognized or mis-
diagnosed without a high index of clinical suspicion on the
part of parents and clinicians. We found it very useful to
show videos of multiple clinical seizure types, both classic
and subtle forms, to parents to increase their likelihood of
recognizing and reporting to clinicians the earliest clinical
events of concern. We also encouraged parents and care-
givers to send video ﬁles obtained with mobile phones for
clinician review and conﬁrmation.
Although an EEG is currently recommended at the time
of initial TSC diagnosis,11,13,18 the results of this study not
only support the importance of that initial EEG but also the
importance of subsequent EEGs in monitoring the devel-
opment of seizures and epileptiform discharges. This
recommendation is consistent with the European recom-
mendation, which suggested close EEG monitoring in the
ﬁrst few months of life and consideration of preventative
treatment in the presence of EEG ictal discharges.19
J.Y. Wu et al. / Pediatric Neurology 54 (2016) 29e3434In conclusion, this study is the ﬁrst multicenter pro-
spective study to evaluate serial EEGs as a biomarker for
subsequent epilepsy in the infant population with TSC. Our
study demonstrates the feasibility and importance of close
EEG surveillance in infants with TSC, with high PPV of
epileptiform discharges for predicting those who subse-
quently develop epilepsy. This interim analysis highlights
the value of early diagnosis of infants with TSC and the
value of serial EEG beginning at the time of diagnosis.
Importantly, our study suggests there is a critical window of
time between emergence of epileptiform discharges and
clinical seizure onset, which provides a unique opportunity
to investigate potentially disease-modifying antiepileptogenic
treatment strategies in this population.
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